Ascendis Pharma A/S reports results for the quarter ended in September - Earnings Summary

Ascendis Pharma A/S

02/11/2022 20:54

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €3.03​​ per share for the quarter ended in September. The
mean expectation of twelve analysts for the quarter was for a
loss of €2.49 per share.
    * Revenue rose 1,273.8% to €15.29 million from a year ago;
analysts expected €8.88 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€3.03​.
    * The mean earnings estimate of analysts had fallen by
about 14.6%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Ascendis Pharma A/S shares had risen by 13.0% this
quarter and
lost 13.2% so far this year.
    * The company reported a quarterly loss of €168.96 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $150.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
2 at 08:53 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -2.49          -3.03          Missed
 Jun. 30 2022      -2.13          -1.46          Beat
 Mar. 31 2022      -2.00          -2.21          Missed
 Dec. 31 2021      -2.34          -1.87          Beat